Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-α to patients with advanced renal cell carcinoma.

被引：0
|
作者：
Smith, JW
Ko, YJ
Dutcher, J
Hudes, G
Escudier, B
Motzer, R
Négrier, S
Duclos, B
Galand, L
Strauss, L
机构：
[1] Providence Portland Med Ctr, Earle Chiles Res Inst, Portland, OR USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Our Lady Mercy Canc Ctr, Bronx, NY USA
[4] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[5] Inst Gustave Roussy, Villejuif, France
[6] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[7] Ctr Leon Berard, F-69373 Lyon, France
[8] CHU Hautepierre, F-67098 Strasbourg, France
[9] Wyeth Ayerst Res, Paris, France
[10] Wyeth Ayerst Res, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4513
引用
收藏
页码：385S / 385S
页数：1
相关论文
共 50 条
  • [31] Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group (ODWG) study.
    Sarantopoulos, J.
    Lenz, H.
    LoRusso, P.
    Shibata, S.
    Kummar, S.
    Mulkerin, D.
    Ramanathan, R. K.
    Mita, M. M.
    O'Rourke, P.
    Remick, S. C.
    Goel, S.
    Gutierrez, M.
    Ramalingam, S. S.
    Murgo, A.
    Davies, A. M.
    Mani, S.
    Boni, J.
    Shapiro, M.
    Ivy, S. P.
    Takimoto, C. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Characterization of hyperglycemia, hypercholesterolemia, and hyperlipidemia in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α
    de Souza, P. L.
    Radulovic, S.
    Beck, J.
    Pendergrass, K.
    Siddique, N.
    Dutcher, J. P.
    Berkenblit, A.
    Thiele, A.
    Krygowski, M.
    Hudes, G. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma.
    McDermott, David F.
    Peer, Avivit
    Agarwal, Neeraj
    Atkins, Michael B.
    Cornell, Jerry
    Perini, Rodolfo F.
    Grossmann, Kenneth F.
    Gurney, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [34] Phase II multi-center study of sintilimab in combination with axitinib in patients with advanced fumarate hydratase-deficient renal cell carcinoma.
    Zhang, Xingming
    Liu, Haoyang
    Zhang, Yaowen
    Zhao, Junjie
    Chen, Yuntian
    Sun, Guangxi
    Sheng, Xinan
    Wang, Yongquan
    Gong, Kan
    Liu, Xiaodong
    Huang, Rui
    Wei, Qiang
    Li, Xiang
    Liu, Jiyan
    Shen, Pengfei
    Chen, Ni
    Yao, Jin
    Liu, Zhenhua
    Zeng, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [35] A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b
    Oza, A. M.
    Elit, L.
    Provencher, D.
    Biagi, J. J.
    Panasci, L.
    Sederias, J.
    Dancey, J. E.
    Tsao, S.
    Eisenhauer, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Phase II study of olaparib in patients with advanced pancreatic acinar cell carcinoma.
    Skorupan, Nebojsa
    Arda, Efsun
    Kozlov, Serguei
    Alewine, Christine Campo
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS789 - TPS789
  • [37] Interferon-α plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: A pilot study
    Robert J. Amato
    Anish Rawat
    Investigational New Drugs, 2006, 24 : 171 - 175
  • [38] Phase I Trial of Sunitinib Malate plus Interferon-α for Patients with Metastatic Renal Cell Carcinoma
    Motzer, Robert J.
    Hudes, Gary
    Wilding, George
    Schwartz, Lawrence H.
    Hariharan, Subramanian
    Kempin, Susan
    Fayyad, Rana
    Figlin, Robert A.
    CLINICAL GENITOURINARY CANCER, 2009, 7 (01) : 28 - 33
  • [39] Interferon-α plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma:: A pilot study
    Amato, RJ
    Rawat, A
    INVESTIGATIONAL NEW DRUGS, 2006, 24 (03) : 171 - 175
  • [40] Interferon-α in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma:: a phase II trial
    Amato, Robert J.
    Jac, Jaroslaw
    Hernandez-McClain, Joan
    ANTI-CANCER DRUGS, 2008, 19 (05) : 527 - 533
12345